Immuron presents pipeline and financial update at Coffee Microcaps conference
The Australian biopharma outlined FY26 revenue growth, a partnering strategy for two clinical assets, and FDA clearance for an IMM-529 Phase 2 study.
SEC filing
Latest
3 stories
Monday, September 21
Tuesday, August 18
Immuron outlines pipeline partnering push at Emerging Growth Conference
CEO Steven Lydeamore's August 19, 2026 presentation detailed FY26 sales, cash position, and plans to license out IMM-124E and IMM-529.
SEC filing (2)
Monday, July 27
Immuron hires Pullan Consulting to shop IMM-529, cites CDI deal comparables
The Australian biopharma also disclosed a new U.S. Department of Defense research pact and first Travelan revenue booked in May 2026.
SEC filing (3)